Viatris settlement in US antitrust case over EpiPen gets final approval
MLex Summary: Viatris’ $264 million settlement to resolve indirect purchasers' claims accusing it of conspiring to delay the market entry of generic EpiPen has been granted final approval by a US...To view the full article, register now.
Already a subscriber? Click here to view full article